argenx NV ADR (ARGX)vsInhibikase Therapeutics Inc (IKT)
ARGX
argenx NV ADR
$1,058.90
+1.13%
HEALTHCARE · Cap: $64.66B
IKT
Inhibikase Therapeutics Inc
$2.47
-0.80%
HEALTHCARE · Cap: $333.49M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 531546899900% more annual revenue ($5.32B vs $1). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 71/100 (B).
ARGX
Strong Buy71
out of 100
Grade: B
IKT
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.2%
Fair Value
$2398.58
Current Price
$1058.90
$1339.68 discount
Intrinsic value data unavailable for IKT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 196.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : IKT
The strongest argument for IKT centers on Altman Z-Score, Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : IKT
The primary concerns for IKT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while IKT is a value play — different risk/reward profiles.
IKT carries more volatility with a beta of 0.95 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (71/100 vs 26/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Inhibikase Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?